Lyndon Kim

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Chemotherapeutic options for primary brain tumors
    Lyndon Kim
    Neuro Oncology Branch, National Cancer Institute and National Institutes of Neurological Disorders and Stroke, National Institutes of Health, Bloch Building 82, 9030 Old Georgetown Road, Bethesda, MD 20892, USA
    Curr Treat Options Oncol 7:467-78. 2006
  2. pmc Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas
    Fabio M Iwamoto
    Neuro Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Cancer 116:1776-82. 2010
  3. pmc A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas
    Teri N Kreisl
    Neuro Oncology Branch, National Cancer Institute, NIH, 9030 Old Georgetown Road, Bloch Bldg 82, Room 225, Bethesda, MD 20892, USA
    Neuro Oncol 12:181-9. 2010
  4. ncbi request reprint A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors
    Howard A Fine
    Neuro Oncology Branch and Medical Oncology Branch, National Cancer Institute, The National Institute of Neurological Disorders and Stroke, Bethesda, Maryland 20892, USA
    Clin Cancer Res 13:7101-6. 2007
  5. pmc Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
    Teri N Kreisl
    Neuro Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 8200, USA
    J Clin Oncol 27:740-5. 2009
  6. doi request reprint A phase I trial of enzastaurin in patients with recurrent gliomas
    Teri N Kreisl
    Neuro Oncology Branch and Biometric Research Branch, National Cancer Institute, National Institute of Neurological Disorder and Stroke, NIH, Bethesda, MD 20892, USA
    Clin Cancer Res 15:3617-23. 2009
  7. doi request reprint Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme
    Camilo E Fadul
    Neuro Oncology Program, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Dartmouth Medical School, Lebanon, NH, USA
    J Neurooncol 89:339-57. 2008

Detail Information

Publications7

  1. ncbi request reprint Chemotherapeutic options for primary brain tumors
    Lyndon Kim
    Neuro Oncology Branch, National Cancer Institute and National Institutes of Neurological Disorders and Stroke, National Institutes of Health, Bloch Building 82, 9030 Old Georgetown Road, Bethesda, MD 20892, USA
    Curr Treat Options Oncol 7:467-78. 2006
    ..Clinical trials implementing angiogenesis inhibitors, biologic modifiers, or molecular-targeted therapies are also actively being investigated...
  2. pmc Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas
    Fabio M Iwamoto
    Neuro Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Cancer 116:1776-82. 2010
    ..Talampanel is an oral AMPA receptor inhibitor with excellent central nervous system penetration and good tolerability in clinical trials for epilepsy and other neurologic disorders...
  3. pmc A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas
    Teri N Kreisl
    Neuro Oncology Branch, National Cancer Institute, NIH, 9030 Old Georgetown Road, Bloch Bldg 82, Room 225, Bethesda, MD 20892, USA
    Neuro Oncol 12:181-9. 2010
    ..Enzastaurin has anti-glioma activity in patients with recurrent high-grade glioma, but does not appear to have enough single-agent activity to be useful as monotherapy...
  4. ncbi request reprint A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors
    Howard A Fine
    Neuro Oncology Branch and Medical Oncology Branch, National Cancer Institute, The National Institute of Neurological Disorders and Stroke, Bethesda, Maryland 20892, USA
    Clin Cancer Res 13:7101-6. 2007
    ....
  5. pmc Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
    Teri N Kreisl
    Neuro Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 8200, USA
    J Clin Oncol 27:740-5. 2009
    ..To evaluate single-agent activity of bevacizumab in patients with recurrent glioblastoma...
  6. doi request reprint A phase I trial of enzastaurin in patients with recurrent gliomas
    Teri N Kreisl
    Neuro Oncology Branch and Biometric Research Branch, National Cancer Institute, National Institute of Neurological Disorder and Stroke, NIH, Bethesda, MD 20892, USA
    Clin Cancer Res 15:3617-23. 2009
    ..Prior phase I studies did not show increased drug exposures with escalating once daily administration. Limits from gastrointestinal absorption may be overcome by twice daily dosing, potentially improving antitumor effects...
  7. doi request reprint Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme
    Camilo E Fadul
    Neuro Oncology Program, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Dartmouth Medical School, Lebanon, NH, USA
    J Neurooncol 89:339-57. 2008